Results 11 to 20 of about 76,116 (300)
The Lancet, 2014 Cholangiocarcinoma represents a diverse group of epithelial cancers united by late diagnosis and poor outcomes. Specific diagnostic and therapeutic approaches are undertaken for cholangiocarcinomas of different anatomical locations (intrahepatic, perihilar, and distal).
Razumilava, Nataliya, Gores, Gregory J
openaire +4 more sources
Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma [PDF]
Cancers, 2021 Cholangiocarcinoma (CCA) is a primary and aggressive cancer of the biliary tree. Combined hepatocellular cholangiocarcinoma (CHC) is a distinctive primary liver malignancy which has properties of both hepatocytic and cholangiocytic differentiation.
Golfieri Rita +2 more
exaly +5 more sources
Digestive and Liver Disease, 2011 Background: Very few studies assessed cholangiocarcinoma clinical characteristics. Aim: To evaluate the clinical characteristics of intra-hepatic (IH) and extra-hepatic (EH)-CCA. Methods: We performed a national survey based on a questionnaire.
Marco Marzioni +2 more
exaly +3 more sources
Critical Reviews in Oncology/Hematology, 2017 Biliary tract cancer accounts for
Michela, Squadroni +5 more
core +4 more sources
Diagnosis of Cholangiocarcinoma
Diagnostics, 2023 Cholangiocarcinoma (CCA), a tumor of the bile duct epithelium, is increasing in incidence. CCA remains a highly fatal malignancy because early diagnosis is difficult. Based on its anatomical location, CCA can be categorized into the following three groups: perihilar, intrahepatic, and extrahepatic.
Dong Woo Shin +2 more
exaly +4 more sources
Nature Reviews Disease Primers, 2021 Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system, which can be classified as intrahepatic, perihilar and distal. Each anatomic subtype has distinct genetic aberrations, clinical presentations and therapeutic approaches.
Paul J. Brindley +8 more
openaire +7 more sources
Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles [PDF]
PeerJ, 2022 Background Cholangiocarcinoma (CCA) is a malignancy of the cholangiocytes. One of the major issues regarding treatment for CCA patients is the development of chemotherapeutic resistance.
Sirinya Sitthirak +10 more
doaj +2 more sources
APOBEC3 activity and DNA polymerase-ε deficiency are associated with distinct IDH1 R132 hotspot mutations. [PDF]
Mol OncolIsocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Butler KE, Lone BA, Unal E, Banday AR.
europepmc +2 more sources
Metabolomic analyses uncover an inhibitory effect of niclosamide on mitochondrial membrane potential in cholangiocarcinoma cells [PDF]
PeerJ, 2023 Background Niclosamide is an oral anthelminthic drug that has been used for treating tapeworm infections. Its mechanism involves the disturbance of mitochondrial membrane potential that in turn inhibits oxidative phosphorylation leading to ATP depletion.
Thanaporn Kulthawatsiri +9 more
doaj +2 more sources
1H NMR fecal metabolic phenotyping of periductal fibrosis- and cholangiocarcinoma-specific metabotypes defining perturbation in gut microbial-host co-metabolism [PDF]
PeerJ, 2023 Background The liver fluke Opisthorchis viverrini (OV), which subsequently inhabits the biliary system and results in periductal fibrosis (PDF), is one of the primarily causes of cholangiocarcinoma (CCA), a bile duct cancer with an exceptionally high ...
Rujikorn Treeriya +12 more
doaj +2 more sources